← Leaderboards
Justin M Balko
Vanderbilt University
$6,825,551
Attributed
$10,452,786
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,452,786 · 9
By mechanism
R01$6,663,892 · 2
P50$1,863,102 · 2
R00$750,172 · 1
P30$608,108 · 2
T32$442,933 · 1
K99$124,579 · 1
Top collaborators
- Douglas B Johnson5 shared
- Javid J Moslehi5 shared
- Julie A Sterling1 shared
- Alissa M Weaver1 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Carlos L Arteaga$27,881,034
- Jennifer A Pietenpol$43,416,854
- William M Grady$22,313,396
- Ken S Lau$11,780,424
- Joshua James Thompson$128,569
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsImmunotherapyTranslatingInstitutionGeneticAntigensResponseAntigen TargetingCell LineMouse ModelTumorMediatingCellsClinical TrialsTissue BanksScreeningSignal TransductionMalignant Breast NeoplasmAffectResearch PersonnelCd8-Positive T-LymphocytesClinical BiomarkersBiopsyCancer Therapy
Grant awards (25)
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis$805,488
R01 · FY2025 · HL · contact PI
Microenvironmental Influences in Cancer$442,933
T32 · FY2025 · CA
Breast Cancer Research Program$339,812
P30 · FY2025 · CA · contact PI
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis$794,337
R01 · FY2024 · HL · contact PI
Breast Cancer Research Program$89,432
P30 · FY2024 · CA · contact PI
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis$815,509
R01 · FY2023 · HL · contact PI
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition$511,114
R01 · FY2023 · CA · contact PI
Targeting antigen presentation to improve immunotherapy responses in breast cancer$335,250
P50 · FY2023 · CA · contact PI
Targeting antigen presentation to improve immunotherapy responses in breast cancer$125,000
P50 · FY2023 · CA · contact PI
Breast Cancer Research Program$89,432
P30 · FY2023 · CA · contact PI
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis$820,373
R01 · FY2022 · HL · contact PI
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition$507,066
R01 · FY2022 · CA · contact PI
Targeting antigen presentation to improve immunotherapy responses in breast cancer$335,248
P50 · FY2022 · CA · contact PI
Breast Cancer Research Program$89,432
P30 · FY2022 · CA · contact PI
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis$832,061
R01 · FY2021 · HL · contact PI
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition$517,415
R01 · FY2021 · CA · contact PI
Targeting antigen presentation to improve immunotherapy responses in breast cancer$383,600
P50 · FY2021 · CA · contact PI
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition$521,546
R01 · FY2020 · CA · contact PI
Targeting antigen presentation to improve immunotherapy responses in breast cancer$348,754
P50 · FY2020 · CA · contact PI
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition$538,983
R01 · FY2019 · CA · contact PI
Targeting antigen presentation to improve immunotherapy responses in breast cancer$335,250
P50 · FY2019 · CA · contact PI
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies$250,586
R00 · FY2017 · CA · contact PI
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies$250,586
R00 · FY2016 · CA · contact PI
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies$249,000
R00 · FY2015 · CA · contact PI
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies$124,579
K99 · FY2014 · CA · contact PI